Angiolab, Inc., a biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases. Its Phase I products consist of AL101-PSO for psoriasis. The company’s Phase II a clinical trial products include AL101- NASH for the treatment of non-alcoholic steatohepatitis; AL101-OME, for otitis media with effusion; and AL102-PDT for periodontitis. Its Phase II clinical trial products comprise AL101-AMD to treat age related muscular degeneration; and AL101-AOB for the treatment of abnormal obesity. In addition, the company provides ob-X for visceral fat reduction; and specific function and health functional food. Further, it offers AL201-AB, which is in the pre-clinical stage for the treatment of cancer, ocular diseases, etc. The company was founded in 1999 and is headquartered in Daejeon, South Korea.
Metrics to compare | 251280 | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship Relationship251280PeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −4.4x | −0.5x | |
PEG Ratio | 0.00 | −0.09 | 0.00 | |
Price/Book | 0.0x | 2.1x | 2.6x | |
Price / LTM Sales | 0.0x | 19.7x | 3.3x | |
Upside (Analyst Target) | 0.0% | 28.1% | 43.5% | |
Fair Value Upside | Unlock | −2.2% | 6.8% | Unlock |